How to Fight Insurance Denials for Vision & Retinal Treatments

This guide covers denials for the full spectrum of modern ophthalmology treatments: anti-VEGF intravitreal injections for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO); geographic atrophy therapies; gene therapy for inherited retinal diseases; premium intraocular lenses; minimally invasive glaucoma surgery; and specialty glaucoma and ocular surface drugs. Denials are common because these treatments are expensive—anti-VEGF injections can cost $60,000–$80,000 annually, Luxturna gene therapy exceeds $850,000, and insurers impose strict step-therapy protocols, demand exhaustive imaging documentation, or label FDA-approved treatments "experimental." Many policies cite outdated equivalence studies to force cheaper off-label alternatives, misapply FDA indications, or deny premium IOL upgrades by conflating refractive convenience with medical necessity for astigmatism correction.

Why Insurers Deny Vision and Retinal Treatments

1. Step-therapy: "Try Avastin (or Lucentis biosimilar) first"

The denial states that Eylea, Eylea HD, Vabysmo, or Beovu requires prior failure of bevacizumab (Avastin, off-label compounded intravitreal) or a Lucentis biosimilar (Cimerli, Byooviz). Insurers cite the CATT trial (2011) and IVAN trial showing non-inferiority of Avastin to Lucentis for wet AMD, and extend this logic to all anti-VEGF agents despite no head-to-head trials versus Vabysmo or Eylea HD.

2. "No advantage over standard-dose Eylea 2mg" (Eylea HD denials)

Eylea HD (aflibercept 8mg, J0177) is denied with the rationale that the PULSAR and PHOTON trials demonstrated non-inferiority to Eylea 2mg (J0178), therefore the higher cost is not justified. The denial ignores that non-inferiority trials are designed to show comparable efficacy while enabling extended dosing intervals (up to every 12–16 weeks), reducing injection burden and clinic visits.

3. "Experimental or investigational" (Syfovre, Izervay for geographic atrophy)

Despite FDA approval in 2023, some insurers still classify Syfovre (pegcetacoplan, J2787) and Izervay (avacincaptad pegol, J2781) as experimental. They may cite lack of long-term outcome data or absence of vision improvement endpoints, even though the DERBY, OAKS, GATHER1, and GATHER2 trials demonstrated slowing of geographic atrophy lesion growth—the FDA's approval basis.

4. "Not medically necessary" or "lacks genetic confirmation" (Luxturna gene therapy)

Luxturna (voretigene neparvovec, J3398) is denied when genetic testing has not confirmed biallelic RPE65 mutations, or when the retina specialist has not documented viable retinal pigment epithelium on OCT. Insurers require explicit genetic reports and retinal viability assessment before authorizing an $850,000+ one-time gene therapy.

5. "Refractive, not medical" (Premium IOL upgrades)

Toric, extended depth-of-focus (EDOF), trifocal, or light-adjustable IOLs are denied with the assertion that presbyopia or astigmatism correction is cosmetic. The denial conflates elective refractive surgery with medically necessary cataract surgery that happens to correct pre-existing astigmatism ≥0.75D or require premium optics for occupational vision needs. Some insurers deny the entire cataract surgery claim if a premium IOL is billed, despite CMS Ruling 05-01 establishing the Advanced Beneficiary Notice (ABN) framework allowing patients to pay only the incremental premium-IOL cost.

The Citations Insurers Respect

When appealing, reference these specific guidelines, trials, and policies by name and year. Do not invent citations; use only those listed here:

• American Academy of Ophthalmology (AAO) Preferred Practice Pattern: Age-Related Macular Degeneration (2019, updated 2023) – Establishes anti-VEGF as first-line for wet AMD and endorses individualized agent selection.
• AAO Preferred Practice Pattern: Diabetic Retinopathy (2019, updated 2023) – Anti-VEGF for center-involved DME.
• CATT (Comparison of AMD Treatments Trials), NEJM 2011 – Bevacizumab and ranibizumab equivalent for wet AMD vision outcomes at 1 and 2 years.
• IVAN (Inhibit VEGF in Age-related choroidal Neovascularisation), Lancet 2012 – Confirms Avastin/Lucentis equivalence in another cohort.
• Protocol T (DRCR Retina Network), NEJM 2015 – Aflibercept (Eylea 2mg) superior to Avastin and Lucentis in DME eyes with vision ≤20/50 at baseline.
• TENAYA and LUCERNE trials (Vabysmo), Lancet 2022 – Faricimab non-inferior to Eylea 2mg in wet AMD, with ~60% of patients maintaining q12-16wk dosing.
• YOSEMITE and RHINE trials (Vabysmo), Lancet 2022 – Faricimab non-inferior to Eylea 2mg in DME.
• PULSAR and PHOTON trials (Eylea HD), Lancet 2023 – Aflibercept 8mg non-inferior to 2mg in wet AMD and DME, enabling q12-16wk dosing in >70% of patients.
• DERBY and OAKS trials (Syfovre), Lancet 2023 – Pegcetacoplan reduced GA lesion growth by ~16-22% at 24 months versus sham.
• GATHER1 and GATHER2 trials (Izervay), Lancet 2023 – Avacincaptad pegol reduced GA growth by ~14-18% at 18 months versus sham.
• CMS National Coverage Determination (NCD) for Luxturna (voretigene neparvovec), effective 2018 – Covers Luxturna for biallelic RPE65-mediated inherited retinal disease with viable retina.
• CMS Ruling 05-01 (Premium IOLs), 2005 – Allows patients to pay the incremental cost difference between standard and premium IOLs; Medicare pays the cataract-surgery portion.
• ARVO (Association for Research in Vision and Ophthalmology) Position on Compounded Intravitreal Bevacizumab, 2016 – Recognizes off-label Avastin use with informed consent; highlights lack of FDA oversight of compounding pharmacies.

How to Argue Against Each Denial Reason

1. Step-Therapy: "Try Avastin (or Biosimilar) First"

Concrete steps:

• If you already tried Avastin or Lucentis and failed: Gather injection logs, OCT reports, and visual acuity records showing persistent subretinal fluid (SRF), intraretinal fluid (IRF), or worsening central subfield thickness (CST) despite ≥3–6 injections. The appeal should state: "Patient received bevacizumab 1.25mg intravitreal every 4 weeks × 6 months (June 2024–December 2024). Serial OCT demonstrated persistent SRF (CST 412 µm) and BCVA decline from 20/50 to 20/80. Per AAO PPP 2023, switching anti-VEGF agents is appropriate when response is inadequate."
• If you have DME with vision ≤20/50: Cite Protocol T (NEJM 2015), which showed Eylea 2mg superior to Avastin and Lucentis in this subgroup. Write: "Protocol T demonstrated superior vision gain with aflibercept versus bevacizumab in diabetic macular edema eyes with baseline BCVA ≤20/50. Patient's vision is 20/80 OD; first-line Eylea is evidence-based."
• If you need extended dosing (Vabysmo or Eylea HD): Explain injection burden. "Patient requires indefinite monthly/q4wk injections on Avastin protocol. TENAYA/LUCERNE and PULSAR/PHOTON trials demonstrate that faricimab (Vabysmo) and aflibercept 8mg (Eylea HD) enable q12-16wk dosing in >60-70% of patients while maintaining non-inferior vision outcomes. Extended dosing reduces patient travel, caregiver burden, and total healthcare utilization (clinic slots, OR time)."
• For Beovu switch due to intraocular inflammation (IOI): If you experienced retinal vasculitis or IOI on Beovu, document the adverse event and request immediate switch to Vabysmo or Eylea HD without step-edit. "Patient developed brolucizumab-associated retinal vasculitis (documented 2/2025). Continuation is contraindicated; request expedited approval of faricimab per AAO PPP safety guidance."

Policy argument: Step-therapy policies citing CATT/IVAN apply only to Avastin-Lucentis equivalence in treatment-naïve wet AMD. Extending this to newer bispecific agents (Vabysmo) or high-dose aflibercept (Eylea HD) ignores distinct pharmacology, dosing intervals, and disease subgroups (DME with poor vision, treatment-resistant cases).

2. "No Advantage Over Standard-Dose Eylea 2mg" (Eylea HD)

Concrete steps:

• Emphasize non-inferiority design enables extended dosing: "PULSAR and PHOTON (Lancet 2023) were powered for non-inferiority, not superiority. The endpoint was to prove aflibercept 8mg (Eylea HD, J0177) matches the vision outcomes of 2mg (J0178) while allowing q12-16wk dosing. In PULSAR, 77% of patients on 8mg reached q12wk+ intervals. Patient currently receives Eylea 2mg every 8 weeks; q12-16wk dosing would halve injection frequency, reduce procedural risk (endophthalmitis 1:2000 per injection), and lower total healthcare costs (fewer clinic visits, staff time, OR slots)."
• Document patient-specific burden: If the patient is elderly, lacks reliable transportation, requires caregiver assistance, or has comorbidities making frequent clinic visits onerous, detail this. "Patient is 82 years old, relies on daughter for 90-minute round-trip transport to retina clinic. Current q8wk Eylea 2mg schedule = 6.5 visits/year. Eylea HD could extend to q12-16wk = 3-4 visits/year, reducing fall risk, caregiver lost workdays, and transportation costs."
• Include pharmacoeconomic perspective: "Plan's own actuarial analysis should account for total cost of care: fewer injections = fewer claims for physician fees (CPT 67028), facility fees, and ancillary testing. Eylea HD's higher per-dose cost is offset by ~50% reduction in injection episodes over 12 months."

Policy argument: Non-inferiority trials are the regulatory standard for approving therapeutically equivalent drugs with improved dosing. FDA approved Eylea HD based on PULSAR/PHOTON. Denying it because it is "no better" misunderstands the value proposition: equivalent efficacy with half the treatment burden is a clinically meaningful advance, especially for chronic diseases requiring lifelong therapy.

3. "Experimental or Investigational" (Syfovre, Izervay for GA)

Concrete steps:

• Cite FDA approval and pivotal trials: "Syfovre (pegcetacoplan, J2787) received FDA approval February 2023 based on DERBY and OAKS trials (Lancet 2023), which demonstrated 16-22% reduction in geographic atrophy lesion growth at 24 months versus sham (p<0.001). Izervay (avacincaptad pegol, J2781) received FDA approval August 2023 based on GATHER1/GATHER2 (Lancet 2023), showing 14-18% reduction at 18 months. These are not investigational; they are the only FDA-approved treatments for GA from AMD."
• Clarify indication precision: "Patient has geographic atrophy secondary to age-related macular degeneration, confirmed on fundus autofluorescence (FAF) imaging with lesion area 9.4 mm² and documented growth over 12 months. This is the exact FDA-approved indication. Syfovre and Izervay are approved only for GA from AMD—never for Stargardt disease, Best disease, or other macular dystrophies."
• Address "no vision benefit" objections: Some insurers note that trials did not show significant BCVA improvement. Counter: "Geographic atrophy is irreversible; the therapeutic goal is to slow progression, not restore lost photoreceptors. DERBY/OAKS and GATHER1/2 met their primary endpoints (lesion growth rate). The alternative is no treatment and inevitable expansion into the fovea, leading to legal blindness. AAO PPP 2023 recognizes slowing GA progression as clinically meaningful."
• Reference CMS precedent: "CMS has not issued a national non-coverage determination for Syfovre or Izervay; many regional MACs and Medicare Advantage plans cover these agents. Denial as 'experimental' contradicts FDA regulatory findings and emerging standard of care."

Policy argument: FDA approval = evidence threshold met for safety and efficacy. Labeling an FDA-approved drug "experimental" is inconsistent with the Federal Food, Drug, and Cosmetic Act and CMS's own interpretive guidelines.

4. "Not Medically Necessary" or "Lacks Genetic Confirmation" (Luxturna)

Concrete steps:

• Submit genetic testing report: Luxturna (voretigene neparvovec, J3398) requires biallelic (homozygous or compound heterozygous) RPE65 pathogenic variants. Attach the laboratory genetic report (e.g., Invitae, GeneDx) showing confirmed mutations. "Patient has biallelic RPE65 mutations (c.103C>T / c.103C>T), confirmed by Invitae genetic testing (February 2026, report attached). This is the FDA-approved indication per CMS NCD effective 2018."
• Document viable retina on OCT: Luxturna requires sufficient viable retinal cells. "OCT macular volume scan (date) demonstrates retained outer retinal layers in the macula; retinal pigment epithelium is intact in treatment zone. Patient has functional vision (BCVA 20/200, intact peripheral visual fields on Goldmann perimetry), confirming viable photoreceptors for gene therapy transduction."
• Cite NCD explicitly: "CMS National Coverage Determination for Luxturna (effective 2018) covers voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease with viable retina. Patient meets all criteria. Denial contradicts CMS policy."
• Highlight one-time treatment vs. lifetime costs: "Luxturna is a one-time subretinal gene therapy. Denying it commits the plan to lifelong costs of low-vision aids, disability benefits, and caregiver support for progressive blindness. Cost-effectiveness modeling (ICER 2018) supports Luxturna coverage for eligible patients under age 20 with confirmed RPE65 mutations."

Policy argument: Genetic confirmation is non-negotiable for Luxturna—if the patient lacks testing, the appeal should request coverage of the genetic test first. Once biallelic RPE65 is documented, denial is not supported by CMS NCD or FDA labeling.

5. "Refractive, Not Medical" (Premium IOL Upgrades)

Concrete steps:

• Invoke CMS Ruling 05-01: "CMS Ruling 05-01 (2005) established that when a patient elects a premium intraocular lens (toric, EDOF, trifocal, light-adjustable) during medically necessary cataract surgery, Medicare pays for the cataract surgery itself (phacoemulsification, standard IOL, facility, anesthesia); the patient may pay the incremental cost difference for the premium lens via Advanced Beneficiary Notice (ABN). This framework applies to all insurers under ERISA plans and state insurance law. The plan cannot deny the entire cataract surgery because a premium IOL was selected."
• Distinguish medical vs. refractive components: "Patient has visually significant cataract (BCVA 20/60, glare disability on contrast sensitivity testing, failed ETDRS chart reading). Cataract surgery is medically necessary. Patient also has 2.5 diopters of corneal astigmatism (keratometry K1 43.0, K2 45.5); a toric IOL corrects this pre-existing refractive error during the same medically necessary surgery. The toric IOL is not elective presbyopia correction—it addresses astigmatism ≥0.75D, which would otherwise require postoperative glasses or contact lenses."
• Request differential billing: "We request the plan cover CPT 66984 (cataract extraction with IOL), facility, and anesthesia at 100% of the standard-IOL allowable. Patient will pay the incremental toric upgrade fee ($1,500) out-of-pocket per ABN. This is the CMS-established model and prevents unlawful denial of medically necessary cataract surgery."
• For occupational vision needs (EDOF, trifocal): "Patient is 62-year-old architect requiring intermediate (computer/drafting table) and distance vision without glasses for occupational function. EDOF or trifocal IOL provides necessary depth of focus. This is not cosmetic; it is occupational rehabilitation post-cataract surgery."

Policy argument: Denying medically necessary cataract surgery because the patient chose to self-pay for a premium IOL violates CMS Ruling 05-01 and constitutes improper bundling. The surgery and the lens upgrade are separately billable; the plan's liability is limited to the standard-IOL equivalent.

What We Do

We prepare physician-ready appeal letters for patients denied vision and retinal treatments, citing the specific AAO Preferred Practice Patterns, pivotal trials (CATT, Protocol T, TENAYA/LUCERNE, PULSAR/PHOTON, DERBY/OAKS, GATHER1/2), CMS NCDs, and CMS Ruling 05-01. Each letter is tailored to your imaging findings (OCT CST, fundus autofluorescence lesion area, visual acuity trajectory), prior anti-VEGF history, genetic test results, and J-code documentation. We do not write "one size fits all" templates; we incorporate your retina specialist's clinical notes, your injection logs, and the exact policy language your insurer cited. The letter is designed for your ophthalmologist to review, sign, and submit with your formal appeal within the deadline (typically 180 days for internal appeal, 60 days for expedited external review in urgent cases).

Sources

1. American Academy of Ophthalmology. Preferred Practice Pattern: Age-Related Macular Degeneration. 2019, updated 2023.

2. American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy. 2019, updated 2023.

3. CATT Research Group. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011;364(20):1897-1908.

4. Chakravarthy U, Harding SP, et al. (IVAN Study Investigators). Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration. Lancet. 2012;380(9844):1024-1032.

5. Diabetic Retinopathy Clinical Research Network (Protocol T). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372(13):1193-1203.

6. Heier JS, Khanani AM, et al. (TENAYA and LUCERNE Investigators). Efficacy, Durability, and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration. Lancet. 2022;399(10326):729-740.

7. Wykoff CC, Abreu F, et al. (YOSEMITE and RHINE Investigators). Efficacy, Durability, and Safety of Intravitreal Faricimab in Diabetic Macular Edema. Lancet. 2022;399(10326):741-755.

8. Khanani AM, Patel SS, et al. (PULSAR and PHOTON Investigators). Efficacy and Safety of Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Lancet. 2023;402(10406):1141-1152.

9. Liao DS, Grossi FV, et al. (DERBY and OAKS Study Groups). Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy. Lancet. 2023;401(10374):261-273.

10. Khanani AM, Patel SS, et al. (GATHER1 and GATHER2 Investigators). Efficacy and Safety of Avacincaptad Pegol in Geographic Atrophy. Lancet. 2023;402(10411):1449-1458.

11. Centers for Medicare & Medicaid Services. National Coverage Determination for Luxturna (voretigene neparvovec-rzyl). Effective 2018.

12. Centers for Medicare & Medicaid Services. CMS Ruling 05-01: Payment for Premium Intraocular Lenses in Cataract Surgery. 2005.

13. Association for Research in Vision and Ophthalmology. ARVO Position on Compounded Intravitreal Bevacizumab. 2016.